成功使用高剂量替加环素和黏菌素联合治疗泛耐药肺炎克雷伯菌肺炎和菌血症。
Successful treatment of pan-resistant Klebsiella pneumoniae pneumonia and bacteraemia with a combination of high-dose tigecycline and colistin.
机构信息
UCLA David Geffen School of Medicine, Department of Pathology and Laboratory Medicine, Los Angeles, CA, USA.
Department of Medicine, Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
出版信息
J Med Microbiol. 2010 Nov;59(Pt 11):1383-1386. doi: 10.1099/jmm.0.023010-0. Epub 2010 Aug 5.
Abstract
The spread of antimicrobial resistance among members of the Enterobacteriaceae is a significant clinical threat. We report the treatment of pan-resistant Klebsiella pneumoniae bacteraemia with combination tigecycline and colistin in a 49-year-old male and review available therapeutic options. Despite a poor prognosis, the patient recovered, but remains colonized with the pan-resistant isolate.
摘要
肠杆菌科成员中抗菌药物耐药性的传播是一个重大的临床威胁。我们报告了一例 49 岁男性泛耐药肺炎克雷伯菌菌血症患者使用替加环素联合黏菌素治疗的情况，并回顾了可用的治疗选择。尽管预后不佳，但患者康复，但仍定植有泛耐药分离株。
相似文献
1
Successful treatment of pan-resistant Klebsiella pneumoniae pneumonia and bacteraemia with a combination of high-dose tigecycline and colistin.
J Med Microbiol. 2010 Nov;59(Pt 11):1383-1386. doi: 10.1099/jmm.0.023010-0. Epub 2010 Aug 5.
2
High-dose tigecycline and colistin for successful treatment of disseminated carbapenem-resistant Klebsiella pneumoniae infection in a liver transplant recipient.
BMJ Case Rep. 2014 Nov 5;2014:bcr2014205865. doi: 10.1136/bcr-2014-205865.
3
NDM-1-producing Klebsiella pneumoniae in Mauritius.
Antimicrob Agents Chemother. 2012 Jan;56(1):598-9. doi: 10.1128/AAC.05639-11. Epub 2011 Oct 17.
4
Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of Klebsiella pneumoniae and Escherichia coli.
Int J Antimicrob Agents. 2012 Mar;39(3):251-4. doi: 10.1016/j.ijantimicag.2011.10.012. Epub 2011 Dec 7.
5
Breakthrough bacteraemia due to tigecycline-resistant Escherichia coli with New Delhi metallo-β-lactamase (NDM)-1 successfully treated with colistin in a patient with calciphylaxis.
J Antimicrob Chemother. 2011 Nov;66(11):2677-8. doi: 10.1093/jac/dkr337. Epub 2011 Aug 16.
6
Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae.
J Antimicrob Chemother. 2017 Jan;72(1):172-180. doi: 10.1093/jac/dkw354. Epub 2016 Sep 19.
7
Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections.
Diagn Microbiol Infect Dis. 2011 Apr;69(4):357-62. doi: 10.1016/j.diagmicrobio.2010.10.013.
8
Efficacy of tigecycline/colistin combination in a pneumonia model caused by extensively drug-resistant Acinetobacter baumannii.
Int J Antimicrob Agents. 2012 Oct;40(4):332-6. doi: 10.1016/j.ijantimicag.2012.06.003. Epub 2012 Jul 24.
9
Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 beta--lactamase-producing Klebsiella pneumoniae epidemic clone.
Diagn Microbiol Infect Dis. 2008 Mar;60(3):319-22. doi: 10.1016/j.diagmicrobio.2007.09.017. Epub 2007 Nov 9.
10
Carbapenem-resistant Klebsiella pneumoniae sepsis in corticosteroid receipt mice: tigecycline or colistin monotherapy versus tigecycline/colistin combination.
J Chemother. 2014 Oct;26(5):276-81. doi: 10.1179/1973947813Y.0000000143. Epub 2013 Dec 6.
引用本文的文献
1
Nutritional analysis and characterization of carbapenemase producing-Klebsiella pneumoniae resistant genes associated with bovine mastitis infected cow's milk.
PLoS One. 2023 Oct 27;18(10):e0293477. doi: 10.1371/journal.pone.0293477. eCollection 2023.
2
Emergence of colistin-resistant gram-negative rods in intensive care units: A cross-sectional study from a developing country.
SAGE Open Med. 2022 Oct 18;10:20503121221132358. doi: 10.1177/20503121221132358. eCollection 2022.
3
Nanotargeting of Resistant Infections with a Special Emphasis on the Biofilm Landscape.
Bioconjug Chem. 2021 Aug 18;32(8):1411-1430. doi: 10.1021/acs.bioconjchem.1c00116. Epub 2021 Jul 28.
4
Antibody-recruiting protein-catalyzed capture agents to combat antibiotic-resistant bacteria.
Chem Sci. 2020 Feb 12;11(11):3054-3067. doi: 10.1039/c9sc04842a.
5
Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections.
Ann Intensive Care. 2020 Jul 13;10(1):94. doi: 10.1186/s13613-020-00715-2.
6
Clinical study on the safety and efficacy of high-dose tigecycline in the elderly patients with multidrug-resistant bacterial infections: A retrospective analysis.
Medicine (Baltimore). 2020 Mar;99(10):e19466. doi: 10.1097/MD.0000000000019466.
7
capsule polysaccharide as a target for therapeutics and vaccines.
Comput Struct Biotechnol J. 2019 Oct 25;17:1360-1366. doi: 10.1016/j.csbj.2019.09.011. eCollection 2019.
8
Case Report of an Extensively Drug-Resistant Infection With Genomic Characterization of the Strain and Review of Similar Cases in the United States.
Open Forum Infect Dis. 2018 Apr 6;5(5):ofy074. doi: 10.1093/ofid/ofy074. eCollection 2018 May.
9
Colistin-resistant in Surgical Polytrauma Intensive Care Unit of Level-1 Trauma Center: First Case Series from Trauma Patients in India.
Indian J Crit Care Med. 2018 Feb;22(2):103-106. doi: 10.4103/ijccm.IJCCM_430_17.
10
High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections: A retrospective cohort study.
Medicine (Baltimore). 2018 Feb;97(8):e9961. doi: 10.1097/MD.0000000000009961.
本文引用的文献
1
Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination.
J Antimicrob Chemother. 2010 Aug;65(8):1807-18. doi: 10.1093/jac/dkq191. Epub 2010 May 31.
2
Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review.
Lancet Infect Dis. 2010 Jan;10(1):43-50. doi: 10.1016/S1473-3099(09)70325-1.
3
Streptococcus pneumoniae coinfection is correlated with the severity of H1N1 pandemic influenza.
PLoS One. 2009 Dec 31;4(12):e8540. doi: 10.1371/journal.pone.0008540.
4
Clonal dissemination of Klebsiella pneumoniae carbapenemase KPC-3 in Long Beach, California.
J Clin Microbiol. 2010 Feb;48(2):623-5. doi: 10.1128/JCM.02397-09. Epub 2009 Dec 23.
5
Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature.
Clin Infect Dis. 2009 Jul 15;49(2):271-4. doi: 10.1086/600042.
6
Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258.
Antimicrob Agents Chemother. 2009 Aug;53(8):3365-70. doi: 10.1128/AAC.00126-09. Epub 2009 Jun 8.
7
Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis.
J Clin Microbiol. 2009 May;47(5):1613. doi: 10.1128/JCM.00404-09.
8
The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria.
Lancet Infect Dis. 2009 Apr;9(4):228-36. doi: 10.1016/S1473-3099(09)70054-4.
9
Success of an infection control program to reduce the spread of carbapenem-resistant Klebsiella pneumoniae.
Infect Control Hosp Epidemiol. 2009 May;30(5):447-52. doi: 10.1086/596734.
10
A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
J Antimicrob Chemother. 2008 Sep;62 Suppl 1:i29-40. doi: 10.1093/jac/dkn249.
Zotero 插件